Hims & Hers Health, Inc. (HIMS)

HIMS expands its AI-powered telehealth platform, boosting personalized care and eyeing international growth in 2026.

Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win?

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how rigorous standards, continuous monitoring, and customer-centered design are shaping the future of safe and effective telehealth. “At Hims & Hers, we believe that digital healthcare must be both accessible and exceptional. Expanding access to millions of people only matters if the care.

Hims & Hers is driving growth through holistic treatment plans, strategic pharma partnerships, and expanded prescription offerings to boost revenue per subscriber. HIMS' recent partnership with Marius Pharmaceuticals for Kyzatrex positions it to capture a larger share of the growing testosterone therapy market and cross-sell to existing users. Despite premium valuation multiples, HIMS maintains strong revenue growth and positive cash flow, justifying investor optimism as it scales new markets and product categories.

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The market often gets worried when a company announces a major change in its C-suite. On news that it was doing just that, on Friday the stock of consumer healthcare company Hims & Hers (HIMS -9.05%) was whacked with a more than 9% sell-off by investors.

PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ --  Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers.  Shareholders of HIMS & HERS may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bergermontague.com   or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or by CLICKING HERE.

HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?

Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primarily due to the announcement that a U.S. federal judge dismissed a lawsuit brought by Eli Lilly against a rival telehealth company, Willow Health, on September 2, 2025.

Amazon's success expanding from books to cloud computing has set the benchmark for the ideal growth stock. By putting the customer first and being willing to take risks, Amazon tremendous wealth for investors.

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $59.12, representing a +1.23% change from its previous close.

Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industries handle administrative tasks.

Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuation reflects high growth expectations, leaving little room for missteps amid FDA scrutiny of compounded GLP-1 marketing and new tariff uncertainties. I'm expecting Hims & Hers to see near-term volatility followed by a break as uncertainty around tariffs and the FDA settles.

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).

Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.